Comment on "Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition".
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22879486.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ray et al. (Reports, 29 July 2011, p. 637) assume that clozapine-N4-oxide (CNO) represents a "biologically inert synthetic ligand" that selectively activates the M4 muscarinic receptor-based DREADD (designer receptor exclusively activated by a designer drug). In contrast, due to the redox cycling of CNO with clozapine and to their cell membrane permeability, CNO is biologically active and its conversion products are capable of undermining DREADD effects.
Medical subject headings
- Body Temperature Regulation
- Chemoreceptor Cells
- Clozapine
- Neural Inhibition
- Neurons
- Respiration
- Serotonin